At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have enough price data to have most value levels, risky levels and pivots.
Achillion Pharmaceuticals, Inc. (ACHN) – has only been below $10 since February 21, 2013.
Affymetrix Inc. (AFFX) – has been below $10 since the week of October 24, 2009.
Agenus Inc. (AGEN) – has been below $10 since the week of April 24, 2010.
Arena Pharmaceuticals, Inc. (ARNA) – has only been below $10 since January 23, 2013.
Array BioPharma, Inc. (ARRY) – has been below $10 since the week of December 29, 2007.
AVEO Pharmaceuticals, Inc. (AVEO) – has been below $10 since the week of October 13, 2012.
BioDelivery Sciences International, Inc. (BDSI) – has been below $10 since the week of October 13, 2012.
BioMimetic Therapeutics Inc. (BMTI) – has been below $10 since the week of May 21, 2011.
Coronado Biosciences, Inc. (CNDO) – has been below $10 since the week of November 26, 2011.
Cytori Therapeutics, Inc. (CYTX) – has been below $9.50 for at least five years.
Dyax Corp. (DYAX) – has been below $7 for at least five years.
Enzon Pharmaceuticals Inc. (ENZN) – has been below $10 since the week of August 6, 2011.
Exelixis, Inc. (EXEL) – has been below $10 since the week of June 18, 2011.
Amicus Therapeutics, Inc. (FOLD) – has been below $10 since the week of October 3, 2009.
GTX Inc. (GTXI) – has been below $10 since the week of November 7, 2009.
ImmunoCellular Therapeutics, Ltd. (IMUC) – has been below $4 for at least five years.
Reading the Table
OV / UN Valued – The stocks with a red number are undervalued by this percentage. Those with a black number are overvalued by that percentage according to ValuEngine. The most undervalued stock is FOLD by 59.6%. The most overvalued stock is ARNA by 59.1%.
VE Rating – A “1-Engine” rating is a Strong Sell, a “2-Engine” rating is a Sell, a “3-Engine” rating is a Hold, a “4-Engine” rating is a Buy and a “5-Engine” rating is a Strong Buy. All sixteen stocks are rated Hold.
Last 12-Month Return (%) – Stocks with a Red number declined by that percentage over the last twelve months. Stocks with a Black number increased by that percentage over the past twelve months! The biggest winner over the last twelve months is BMTI with a gain of 343.1%. The biggest loser was FOLD with a loss of 53.6%.
Forecast 1-Year Return – Stocks with a Red number are projected to decline by that percentage over the next twelve months. Stocks with a Black number in the Table are projected to move higher by that percentage over the next twelve months. These stocks are projected to trade between a decline of 3.7% and a gain of 3.2% over the next twelve months.
P/E Ratios – The twelve month trailing P/E ratios. Only one has a P/E ratio of 34.9 (ENZN).
Value Level: is the price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.
Pivot: A level between a value level and risky level that acts as a magnet during the time frame noted.
Risky Level: is the price at which to enter a GTC Limit Order to sell on strength.
Where to Buy and Where to Sell
A “Value Level” is a price at which buyers should add to positions on market price weakness. A “Risky Level” is a price at which sellers should reduce holdings on market price gains. A "Pivot" is a support or resistance (Value Level or Risky Level) that was violated in its time horizon, acting as a magnet during the remainder of that time horizon. These levels are calculated in weekly (W), monthly (M), quarterly (Q), semiannual (S) and annual (A) time horizons, based on the past nine closes in each time horizon. My theory is that the closes over a nine-year period are the summation of all bullish and bearish events for that market or specific stock. These levels are the most important element of my Buy and Trade Strategy.
Buy and Trade Guidelines
Investors should consider entering good until cancelled (GTC) orders to buy weakness to a value level, or to sell strength to a risky level.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer